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Hyperhomocysteinemia, anticardiolipin antibody status, and risk for polytetrafluoroethylene (PTFE) graft, which has a higher
vascular access thrombosis in hemodialysis patients. rate of graft failure. In fact, patency rates at one and
Background. Vascular access failure is an important cause of mor-
two years for PTFE grafts are only 50% to 65% andbidity in end-stage renal failure patients on hemodialysis. Currently,
little is known about risk factors that predispose certain hemodialysis 50%, respectively [1, 2, 4–6]. The most common cause
patients to recurrent access thrombosis. Hyperhomocysteinemia (com- of vascular access failure is graft thrombosis [7]. Because
mon in patients with renal failure) predisposes people with normal
patients may be supported on hemodialysis for years torenal function to recurrent and early-onset venous thrombosis, al-
though the effect on vascular access thrombosis is currently unknown. decades, graft thrombosis is a major clinical problem,
Previous studies have suggested that high titers of IgG anticardiolipin accounting for an average of 17% of hemodialysis patient
antibody (IgG-ACA) predispose hemodialysis patients to access
admissions to one center [8]. In addition to the significantthrombosis. This cross sectional study was designed to assess for an
association between two predictive variables, hyperhomocysteinemia morbidity created by access failure, it has been estimated
and elevated titers of IgG-ACA, and vascular access thrombosis in that $500 million is spent each year in the United States
patients undergoing chronic hemodialysis.
to create and maintain vascular access [9].Methods. Risk factors for vascular access thrombosis were docu-
mented, and the number of episodes of access thrombosis was recorded Little is known about risk factors for vascular access
for the previous three years in patients undergoing hemodialysis. Mid- thrombosis [1]. It is accepted that low blood flow throughweek predialysis total homocysteine and IgG-ACA levels were mea-
the graft resulting from stenosis or neointimal hyperpla-sured in all subjects.
Results. Of the 118 patients who were enrolled, 75.4% had a native sia at the site of the venous anastomosis increases the
arteriovenous fistula. Episodes of vascular access thrombosis were re- likelihood of thrombosis [5, 10]. However, this is onlycorded for the previous three years; 34 (28.8%, 95% CI 20.9 to 37.9%)
a marker for thrombosis and not a risk factor for itspatients had 72 episodes of access thrombosis over the period of risk.
Mean homocysteine levels were not significantly different between development. Currently, the only definite risk factor for
these 34 patients (28.6 mmol/liter, 95% CI 24.5 to 32.7) and the patients vascular access thrombosis is placement of a syntheticwho had no episodes of graft thrombosis (29.8 mmol/liter, 95% CI 26.7
graft rather than a native AVF [2–4, 11]. Risk factorsto 32.9). Sixty-seven unselected patients had IgG-ACA levels drawn
for analysis, and all assays were negative. The only variable that was that have been suggested in single studies but not con-
associated with a higher risk for graft thrombosis was the type of firmed by other analyses include the presence of diabetesvascular access placed (odds ratio 4.0, 95% CI 1.6 to 9.6 for patients with
[3], the location of the graft [4], the age of greater thana synthetic graft compared with those with an arteriovenous fistula).
Conclusions. No association was found between homocysteine lev- 65 years [11], the time until use of graft after surgical
els or anticardiolipin antibody and vascular access thrombosis in our creation [4], hypoalbuminemia [2], and elevated lipopro-patient population.
tein(a) [13].
Hyperhomocysteinemia has been reported to be asso-
ciated with early-onset venous thrombosis [14] and recur-Vascular access is necessary for hemodialysis. Long-
rent venous thrombosis [15] in patients without end-term access is best achieved with a native arteriovenous
stage renal disease (ESRD). Patients with chronic renalfistula (AVF) [1–4], but inadequate arterial and venous
failure have homocysteine levels twofold to fourfoldanatomy frequently necessitate creation of a synthetic
higher than patients with normal renal function [16–19].
Currently, no published studies have measured the asso-
ciation between hyperhomocysteinemia and vascular ac-Key words: hyperhomocysteinemia, ESRD, IgG-ACA, arteriovenous
fistula, graft thrombosis. cess thrombosis in patients on hemodialysis.
Immunoglobulin-G anticardiolipin antibody (IgG-Received for publication March 12, 1998
ACA) is strongly associated with venous and arterialand in revised form June 29, 1998
Accepted for publication August 19, 1998 thrombosis in patients with normal renal function [20].
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modialysis patients [21]. There are conflicting reports years, as well as possible risk factors for access thrombo-
sis. All information was confirmed by careful review ofregarding the association between elevated titers of ACA
and vascular access thrombosis in patients on hemodialy- each participant’s hospital chart, surgical record, and
outpatient dialysis record.sis [21–25]. In one study by Prakash, Miller and Suki,
the odds ratio for experiencing more than two episodes
Outcome variablesof graft thrombosis over a 2.5 year period in patients
with an elevated IgG-ACA level was 3.7 (95% CI 1.2 Risk factors for vascular access thrombosis. Informa-
tion on type of vascular access (native AVF or PTFEto 11.8) [23]. This relationship was only noted among
patients with synthetic grafts. graft), graft location, patient race and age, and etiology
of renal failure was recorded. Diabetes mellitus was con-The purpose of this study was to determine whether
hyperhomocysteinemia and/or elevated levels of IgG- sidered present if the patient was on insulin, oral hypo-
glycemics, or a diabetic diet, or if the patient’s fastingACA are associated with vascular access thrombosis in
patients with ESRD undergoing chronic hemodialysis. or random plasma glucose was more than 7.8 mmol/liter
or more than 11.1 mmol/liter, respectively. A patient was
considered a smoker if they were a current smoker, an ex-
METHODS
smoker if they had smoked in the past, or a nonsmoker if
Subjects and protocol they had never smoked. The use of interdialytic anticoag-
ulants (such as coumadin) was recorded.The Conjoint Medical and Research Ethics Board at
the University of Calgary approved the study protocol. Diagnosis of vascular access failure and thrombosis.
Vascular access failure was defined as failure of the ac-All study subjects provided written informed consent.
This was a cross-sectional study involving patients with cess due to any cause requiring surgical intervention.
Radiological intervention (such as angioplasty) was notESRD receiving hemodialysis in a centralized dialysis unit.
In our dialysis unit, approximately 75% of patients recorded for this study, although in our dialysis unit,
radiologists do not perform declotting or thrombolysishad native AVFs, and no patients used bioincompatible
dialysis membranes. Eighty-seven percent of patients procedures. For the purposes of this study, vascular ac-
cess failure was divided into primary and secondary graftused polysulfone, 8.6% used cellulosynthetic, 3.6% used
cellulose acetate, and 0.9% used polyacrylonitrile mem- failure. Primary graft failure was defined as the failure
of patency within the first 30 days after placement [7],branes. No dialyzer reuse occurred in this unit. The aver-
age blood flow was 300 to 400 ml/min. The average length which is generally considered a surgical problem. We
only considered secondary graft failure for the purposesof each dialysis was four hours, and the adequacy of
dialysis was assessed on a monthly basis using the Kt/V. of this analysis, and we classified the cause of secondary
vascular access failure as being related to thrombosis orAt the time that this study was completed, there was
no routine screening program in place to detect venous to other causes (such as infection or pseudoaneurysm).
Vascular access thrombosis was defined as the lackoutlet stenosis. In our unit, if thrombosis of a synthetic
graft occurred, a surgical declotting procedure was per- of blood flow by palpation and auscultation [10]. The
presence of thrombus was confirmed by angiography orformed if possible, and venous outlet stenosis was treated
with a coronary dilator intraoperatively. Eighty-four per- surgery. In order to account for the fact that many sub-
jects in this study had their vascular access for less thancent of patients in our dialysis unit were on supplementa-
tion with a multivitamin containing 1 mg of folic acid, three years and therefore were at risk of thrombosis
for a shorter period, we also calculated rates of graft6 mg of vitamin B12, and 10 mg of vitamin B6, either on
a daily basis or three times per week. thrombosis per year. Patients were divided into three
groups based on their rates of graft thrombosis: a throm-Exclusion criteria for this study were refusal or inabil-
ity to give informed consent, never having had a function- bosis-free group with no episodes of graft thrombosis
per year, an infrequent thrombosis group with more thaning permanent hemodialysis access (that is, AVF or PTFE
graft), and the requirement for short-term (that is, less zero but less than one episode of graft thrombosis per
year, and a recurrent thrombosis group with more thanthan two months) dialysis only. Of 221 patients who were
dialyzed in this unit, 183 patients were eligible for this one episode of graft thrombosis per year.
trial on the basis of having a permanent access. Of the
Laboratory investigationseligible patients, 131 patients (72%) provided informed
consent. Of those, 118 patients had all of the necessary Homocysteine. Plasma total homocysteine concentra-
tions were determined by reverse phase high pressureblood work completed.
Midweek predialysis blood samples were collected from liquid chromatography (HPLC) using the method devel-
oped by Vester and Rasmussen [26] and further modifiedall participants for total homocysteine and IgG-ACA
levels. Information was recorded for each patient regard- by Ubbink et al [27]. Ingestion of food has little effect
on homocysteine levels [27, 28], whereas hemodialysising history of vascular access thrombosis in the past three
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Table 1. Baseline patient characteristics for the entire group andmay decrease levels by 30% [28]. Hence, predialysis non-
for those with an anticardiolipin antibody assay
fasting midweek levels were measured for all patients.
Subgroup inBlood samples were collected and spun to plasma within
which IgG-ACA30 minutes of collection. Samples were stored at 2708C, All patients was assayed
and all assays were conducted in one batch. The refer- Patient characteristic (95% CI) (95% CI)
ence range as determined in our research laboratory for Number of patients 118 67
Age mean in years 61.0 (58.2–63.8) 60.9 (56.9–64.9)patients with normal renal function was 7.0 to 14.2 mmol/
Sex male 68.6% (59.5–76.9) 65.5% (53.1–76.8)liter (mean 10.6 mmol/liter, sd 1.6 mmol/liter).
Type of graft
Anticardiolipin antibody (ACA). IgG-ACA levels AVG 75.4% (66.7–82.9) 83.6% (72.5–91.5)
PFTE graft 24.6% (17.1–33.3) 16.4% (8.5–27.5)were measured using a commercial ELIZA kit (Hema-
Diabetic 36.1% (27.2–44.9) 25.5% (15.5–37.5)gen, Waltham, MA, USA). Positive and negative con-
Smoking status
trols were included in each batch assay. Normal values Never 42.0% (32.5–50.9) 41.8% (29.8–54.5)
Ex-smoker 41.2% (31.8–50.1) 36.4% (24.5–48.5)were less than 10 IgG phospholipid units (GPL). Positive
Smoker 15.8% (10.0–24.0) 21.8% (13.1–34.2)assays are graded into low, moderate, and highly positive
Graft location
as follows: 11 to 20 GPL, 21 to 80 GPL, and more than (proximal to elbow) 14.4% (8.6–22.1) 15.5% (7.4–25.7)
Erythropoietin use 79.5% (70.3–85.8) 85.5% (74.3–92.6)80 GPL [29].
Interdialytic use of
anticoagulants 11.0% (6.0–18.1) 13.4% (6.3–24.0)Statistical methods
Use of folic acid
supplementationa 84.0% (76.0–90.0) 87.3% (64.2–85.7)Baseline variables were described using mean, geomet-
Mean homocysteinerical mean, or proportions and confidence intervals where
lmol/liter 29.4 (26.8–32.0) 29.4 (26.6–32.2)
appropriate. The primary hypothesis of this study—
Abbreviations are: AVF, arteriovenous fistula; PTFE, polytetrafluoroethylene.hyperhomocysteinemia is associated with vascular access a Mean dose 0.57 mg folic acid/day (0.47–0.67)
thrombosis in patients with ESRD on hemodialysis—was
tested using three complementary statistical methods.
First, a two-sample, two-sided t-test was used to compare
mellitus 26%, glomerulonephritis 20%, hypertensionmean homocysteine levels between patients with and
7%, polycystic kidney disease 7%, reflux nephropathywithout an episode of graft thrombosis over the period
4%, interstitial nephritis 3%, other 19%, and unknownat risk. Second, one-way analysis of variance was used
14%. The mean homocysteine level was 29.4 mmol/literto assess for a difference between mean homocysteine
(95% CI 26.8 to 32.0; range 11.2 to 116.8). Mean redlevels in the thrombosis-free group, the infrequent throm-
blood cell folate and vitamin B12 levels were 1699 mmol/bosis group, and the recurrent thrombosis group. Finally,
liter (95% CI 1574 to 1804; normal more than 250), andlogistic regression was done using a history of one or more
448 pmol/liter (95% CI 405 to 491; normal more thanepisodes of graft thrombosis as the outcome variable.
130), respectively.Backward elimination was then performed by sequen-
Of the 118 study patients, 50 (42.4%, 95% CI 33.3 totially removing predictor variables where the P value
51.8%) patients had 117 episodes of vascular access fail-was more than 0.10.
ure requiring surgical intervention. Thirty-four (28.8%,The secondary hypothesis of this study—the presence
95% CI 20.9 to 37.9%) patients had 72 episodes of throm-of IgG-ACA is associated with vascular access thrombo-
bosis as the cause of vascular access failure. Accesssis in patients with ESRD on hemodialysis—was tested
thrombosis was analyzed for the three years precedingusing Fisher’s exact test.
this study. Because some subjects had had their accessResults were considered significant if the P value was
for less than three years, the mean observation time overless than 0.05. Ninety-five percent confidence intervals
which subjects were at risk for thrombosis was actuallywere used for means, whereas binomial exact 95% con-
two years (95% CI 1.84 to 2.16 years). Table 2 demon-fidence intervals were used for proportions.
strates absolute numbers and rates of vascular access
thromboses for patients in this study according to type
RESULTS of vascular access.
All of the 118 patients enrolled in this study had all Mean homocysteine levels were not significantly dif-
of the necessary blood work collected. Baseline patient ferent between those patients who had at least one docu-
characteristics are described in Table 1. Approximately mented episode of vascular access thrombosis (28.6
three quarters of the patients had a native AVF, whereas mmol/liter, 95% CI 24.5 to 32.7) and those patients who
one quarter of patients had a synthetic PTFE graft. Sev- had no episodes of access thrombosis (29.8 mmol/liter,
enty-nine percent of sampled patients were white, 8% 95% CI 26.7 to 32.9; mean difference 1.2 mmol/liter; 95%
Asian, 4% Native Indian, 2% African American, and CI 24.5 to 7.0). Similarly, when patients with homocys-
teine levels below the median were compared with those7% other. The etiology of renal failure was diabetes
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Table 2. Number and rates of graft thrombosis according to type of vascular access
All grafts AVF PTFE graft
(95% CI) (95% CI) (95% CI)
Number of graft thromboses in period at risk
0 episodes 71.2% (62.1–79.1) 78.7% (68.7–86.6) 48.3% (29.5–67.5)
1 episode 15.3% (9.3–23.0) 14.6% (8.0–23.7) 17.2% (5.8–35.7)
2 episodes 5.9% (2.4–11.8) 3.4% (0.7–9.5) 13.8% (3.9–31.6)
.2 episodes 7.6% (3.5–14.0) 3.4% (0.7–9.5) 20.7% (8.0–39.7)
Rates of graft thromboses/year
0 episodes/year 71.8% (62.1–79.1) 78.7% (68.7–86.6) 48.3% (29.5–67.5)
.0 and ,1 episode/year 16.1% (10.0–24.0) 14.6% (8.0–23.7) 20.7% (8.0–39.7)
. or 51 episode/year 12.7% (7.3–20.1) 6.7% (2.5–14.1) 31.0% (15.3–50.8)
Table 3. Mean homocysteine levels in the thrombosis-free, infrequent thrombosis, and recurrent thrombosis groups
according to type of vascular access
Mean homocysteine (95% CI), lmol/liter
All subjects Native AVF PTFE graft
Rate of thrombosis during time at risk (N 5 118) (N 5 89) (N 5 29)
0 episodes/year 29.8 (27.0–32.5) 28.4 (25.9–30.9) 36.6 (27.2–46.4)
.0 and ,1 episode/year 26.3 (24.6–28.0) 25.7 (24.0–27.4) 27.5 (22.7–32.3)
.1 episode/year 31.5 (28.8–34.2) 35.5 (32.3–38.7) 28.9 (22.6–34.2)
ANOVA P 5 0.52 P 5 0.24 P 5 0.54
Table 4. Multiple logistic regression using previously reported risk the only variable that was independently associated with
factors to predict for one or more episodes of graft thrombosis
access thrombosis was the type of access created (odds(prior to backwards elimination)
ratio 4.0, 95% CI 1.6 to 9.6 for patients with a synthetic
Risk factors Odds ratio 95% CI P value graft).
Plasma homocysteine 0.99 0.96–1.02 0.682 There was a trend toward an association between
Age years 0.98 0.95–1.01 0.137
younger age and increased rates of vascular access throm-PTFE graft 4.20 1.51–11.7 0.006
Current smoker 2.41 0.90–6.42 0.079 bosis. The odds ratio of having one or more episodes of
Graft proximal to elbow 1.28 0.80–2.06 0.308 access thrombosis for patients over the age of 65 was
Peripheral vasc. dis. 1.39 0.44–4.40 0.578
0.47 (95% CI 0.21 to 1.07, P 5 0.07). There was noDiabetes mellitus 0.86 0.32–2.33 0.765
association found between vascular access thrombosis
and smoking, diabetes, graft location, or presence of
peripheral vascular disease.
Sixty-seven unselected patients had IgG-ACA levelsabove the median level, the percentage having had an
drawn for analysis. All IgG-ACA assays were negativeepisode of access thrombosis was not different (30.0%,
95% CI 18.8 to 43.2 vs. 27.6%, 95% CI 16.6 to 40.9). (mean 2.4 GPL, sd 1.3; normal IgG-ACA less than 10
When the mean homocysteine levels were compared for GPL). Because of the uniformly negative test results, no
the thrombosis free, the infrequent thrombosis, and the further assays were conducted, as it was very unlikely any
recurrent thrombosis groups using analysis of variance, association would be demonstrated with further testing.
there was no significant difference (Table 3). This analy- The baseline characteristics of these 67 patients were
sis was repeated separately for patients with native AVFs similar to the overall group (Table 1), and the rate of
and synthetic grafts, and there also was no significant access thrombosis was also not different. Therefore, this
association found between homocysteine levels and rates subgroup appeared to be representative of the overall
of thrombosis for the two types of vascular accesses sample.
(Table 3).
Logistical regression analysis, using a history of access
DISCUSSIONthrombosis as the outcome variable and controlling for
Despite the fact that the majority of patients enrolledpreviously postulated risk factors for access thrombosis
in this study had native AVFs, vascular access thrombosisas predictor variables, did not reveal homocysteine to
was still a major problem and occurred in nearly onebe independently associated with access thrombosis (Ta-
third of patients over the average risk time of two years.ble 4). After performing backward-elimination logistical
regression using the model in Table 4 as a starting point, Access thrombosis was much more common in patients
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with synthetic grafts. Thirty-one percent of the patients thetic grafts. There was no association found between
hyperhomocysteinemia and access thrombosis for eitherwith synthetic grafts had more than one episode of
thrombosis per year at risk compared with only 6.7% of type. At the time of this study, our dialysis unit had no
screening program to detect or correct venous outletpatients with AVFs. Our results are similar to those
found in the Canadian Hemodialysis Morbidity Study, stenosis. The lack of a screening program, in fact, pro-
vided the best opportunity to demonstrate an associationa large multicenter prospective cohort study of first per-
manent vascular access survival among incident hemodi- between homocysteine levels and access thrombosis if
one had existed, since a prophylactic regimen correctingalysis patients, which demonstrated a 55% reduction in
episodes of graft thrombosis for patients with AVFs com- all venous outlet stenoses may have dramatically reduced
the number of access thromboses [33]. Because thrombo-pared with synthetic grafts [2].
There was a trend toward an increased risk of access sis is usually preceded by venous outlet stenosis for syn-
thetic grafts or draining vein stenosis for AVFs, our studythrombosis in patients younger than 65 years of age,
which was strongest for patients with an AVF. This is suggests that hyperhomocysteinemia does not predispose
to vascular disease or stenosis in veins as it does in arteries.unlike the findings of a cross-sectional study done using
United States Renal Data System data, which noted a lower Previous studies have reported elevated IgG-ACA
levels in 0.7 to 69% of patients with ESRD on hemodialy-risk of vascular access failure among patients under the
age 65 who were using native AVFs [11]. sis [21]. Sitter and Schiffl have reported elevated IgG-
ACA titers more commonly in patients on hemodialysis,Despite previous reports that hyperhomocysteinemia,
in patients with normal renal function, is associated with occurring in 17% of patients on hemodialysis and in only
5% of patients on peritoneal dialysis [21]. Garcia-Martinearly-onset venous thrombosis [14] and recurrent venous
thrombosis [15], our study found no association between et al found that patients dialyzing with cuprophane mem-
branes had a higher prevalence of positive ACA assayshomocysteine levels and vascular access thrombosis.
There also was no trend demonstrated toward increasing than those dialyzed with more biocompatible membranes
[34]. Prakash et al found significant titers of IgG-ACAhomocysteine levels in those patients who experienced
recurrent vascular access thrombosis. There was no sig- in 22% of patients with a synthetic graft and only in 6% of
patients with native AVFs [23]. These three observationsnificant effect of elevated homocysteine levels on access
thrombosis noted for patients with native AVFs or syn- suggest that production of the ACA may be a reaction
to material present in the synthetic graft or to foreignthetic grafts. We feel this study had adequate power to
detect a clinically important association between hyper- substances to which the patient is exposed during hemo-
dialysis.homocysteinemia and access thrombosis if one had been
present. With a sample size of 118, using a two-sided Previous retrospective studies have reported an associ-
ation between elevated IgG-ACA levels and vascularP value and using variability estimates for homocysteine
as determined in our data set, our study had a power of access thrombosis in patients on hemodialysis [21, 23–
25]. No prospective studies have confirmed this finding,0.82 to detect a difference in homocysteine levels of 25%
between patients with and without a history of graft which has been noted mostly in patients dialyzing with
synthetic grafts. In our study, we measured IgG-ACAthrombosis.
Since conducting our study, there have been three levels because it is the isotype that correlates best with
thrombosis in patients with SLE and primary antiphos-retrospective reports published on the association be-
tween homocysteine and access thrombosis, all with pholipid syndrome [20, 23]. No patients in our study had
an elevated IgG-ACA level, and hence, there was nofewer patients than this report. Two have been in abstract
form and, in general, have supported the findings of this demonstrable association found between ACA and vas-
cular access thrombosis. It is noteworthy that only 16.4%study. The first abstract reported no association between
hyperhomocysteinemia and recurrent vascular access of patients in our study had synthetic grafts and that no
patient used a cuprophane dialysis membrane.thrombosis in hemodialysis patients with synthetic grafts
(N 5 45) [30], whereas the second noted a small inverse The results of our study suggest that high titers of
IgG-ACA are not an important predisposing factor torelationship between hyperhomocysteinemia and vascu-
lar access thrombosis (N 5 98) [31]. A recent, small graft thrombosis in patients who use predominantly na-
tive AVFs and biocompatible membranes.study by Ducloux et al (N 5 39) revealed significantly
higher homocysteine levels in patients with recurrent In summary, this study demonstrates a high risk of
graft thrombosis in patients undergoing hemodialysis.access thrombosis compared with those with one or less
episodes of thrombosis [32]. Although the results were The only definite association noted for graft thrombosis
in this study was the type of graft placed. There was nostatistically significant, it is unclear what type of vascular
access was studied, and concern should be given to such association found between homocysteine levels or ACA
and vascular access thrombosis in our patient population.a small sample size.
Our study included patients with both AVFs and syn- Currently, there does not appear to be a role for mea-
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